

Bit Market Services

Informazione Regolamentata n. 0472-4-2016	Data/Ora Ricezione 13 Gennaio 2016 18:13:18	MTA - Star
---	---	------------

Societa' : BB BIOTECH

Identificativo : 67942

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : IRAG 10

Data/Ora Ricezione : 13 Gennaio 2016 18:13:18

Data/Ora Inizio : 13 Gennaio 2016 18:28:18

Diffusione presunta

Oggetto : BB Biotech AG earns after-tax profits of
CHF 653 million in fiscal 2015

Testo del comunicato

Vedi allegato.

Media Release, January 13, 2016

BB Biotech AG earns after-tax profits of CHF 653 million in fiscal 2015

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its profits in fiscal 2015.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the past year with a profit of CHF 653 million (profit of CHF 1'470 million in the previous year). After a quarterly loss of CHF 575 million in the third quarter, BB Biotech AG made a profit of CHF 511 million in the last quarter of 2015.

The net profit figure for 2015 reflects the fundamental strength of the biotech sector and the successful investment strategy pursued by BB Biotech AG with clearly defined areas of focus. The increased volatility on stock markets in the second half year of 2015 led to heavily varying quarterly results.

Portfolio holdings as of December 31, 2015 will be reported on January 22, 2016. The annual report for 2015 will be published on February 19, 2016.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch
www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 4.0 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-4

Numero di Pagine: 3